iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Rhea-AI Summary

iBio (NASDAQ:IBIO) will host a corporate update call on March 17, 2026 at 4:00 p.m. ET to discuss expansion into pulmonary hypertension associated with HFpEF (PH-HFpEF) and its engineered selective bispecific antibody program.

iBio expects to select an optimized bispecific development candidate in Q3 2026 before starting IND-enabling activities.

Key Figures

Shelf registration size: $200,000,000 ATM common stock capacity: $100,000,000 ATM commission rate: 3.0% +5 more

8 metrics

Shelf registration size $200,000,000 Form S-3 securities capacity filed February 27, 2026

ATM common stock capacity $100,000,000 Common stock under Open Market Sales Agreement in S-3

ATM commission rate 3.0% Jefferies sales agent commission on ATM proceeds

Shares outstanding 34,543,561 shares As of February 24, 2026 per S-3 prospectus

Warrants exercisable 127,598,048 warrants Shares issuable upon exercise as of February 24, 2026

Share price $2.39 Pre-news trading price on analysis date

52-week high $5.60 52-week trading range high

52-week low $0.5562 52-week trading range low

Market Reality Check

Price: $2.39 Vol: Volume 548,037 is below t...

low vol

$2.39 Last Close

Volume Volume 548,037 is below the 20-day average of 1,053,872, suggesting a relatively subdued pre-news trading session. low

Technical Shares at $2.39 were trading above the 200-day MA of $1.37, reflecting a recovery from prior lows.

Peers on Argus

IBIO was moving up with a 0.82% gain while momentum-screened peer NBY was down 8...

1 Down

IBIO was moving up with a 0.82% gain while momentum-screened peer NBY was down 8.28% and other biotech peers showed mixed moves, indicating a stock-specific rather than sector-wide move.

Historical Context

5 past events · Latest: Mar 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 09	Preclinical obesity data	Positive	-4.2%	Reported IBIO-610 NHP data showing visceral and total fat mass reductions.
Feb 24	Conference participation	Neutral	+0.8%	Announced executive participation in upcoming healthcare investor conferences.
Feb 10	Earnings and update	Positive	-2.6%	Reported Q2 FY2026 results plus financing that extended cash runway.
Jan 09	Private placement	Positive	+14.9%	Announced $26M private placement to fund cardiometabolic and obesity programs.
Nov 24	Conference appearance	Positive	+5.4%	Outlined obesity pipeline progress ahead of Evercore healthcare conference.

Pattern Detected

Recent positive pipeline and financing news often saw mixed or even negative next-day price reactions, indicating uneven alignment between fundamentals updates and short-term trading.

Recent Company History

Over the past several months, iBio has focused on financing and pipeline-building. A $26M private placement in January 2026 and Q2 FY2026 results strengthened its cash position for obesity and cardiometabolic programs. Subsequent preclinical IBIO-610 data on March 9, 2026 were positive but met with a short-term share decline. Conference participation updates in November 2025 and February 2026 coincided with modest gains. Today’s cardiopulmonary PH-HFpEF program update fits this pattern of broadening the antibody pipeline funded by recent capital raises.

Regulatory & Risk Context

Active S-3 Shelf · $200,000,000

Shelf Active

Active S-3 Shelf Registration 2026-02-27

$200,000,000 registered capacity

iBio has an effective Form S-3 shelf filed on February 27, 2026, registering up to $200,000,000 of securities, including up to $100,000,000 of common stock under an Open Market Sales Agreement with Jefferies. The company has already used this shelf via a 424B5 filing on March 6, 2026, enabling at-the-market issuance that can introduce ongoing dilution as shares are sold over time.

Market Pulse Summary

This announcement highlights iBio’s expansion into PH-HFpEF with a selective bispecific antibody tar...

Analysis

This announcement highlights iBio’s expansion into PH-HFpEF with a selective bispecific antibody targeting Activin A, GDF8, and GDF11, aiming to address fibrosis and pulmonary vascular remodeling. It extends a broader cardiometabolic strategy funded by recent financings and supported by an effective $200,000,000 S-3 shelf and $100,000,000 ATM capacity. Investors may watch for selection of the optimized development candidate in Q3 2026, IND-enabling progress, and how the company balances pipeline growth with potential dilution from at-the-market share sales.

Key Terms

pulmonary hypertension, heart failure with preserved ejection fraction, PH-HFpEF, bispecific antibody, +1 more

5 terms

pulmonary hypertension medical

"strategic pipeline expansion into pulmonary hypertension associated with heart failure..."

Pulmonary hypertension is a condition where the blood vessels in the lungs become narrowed or stiff, forcing the right side of the heart to work much harder to push blood through—imagine a pump trying to push water through narrower pipes. For investors, it matters because the condition drives demand for diagnostic tests, ongoing treatments, and new drugs; changes in clinical trial results, approvals, or treatment guidelines can meaningfully affect the commercial prospects and costs for companies focused on this disease.

heart failure with preserved ejection fraction medical

"pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF)"

A form of heart disease where the heart muscle pumps out a normal share of blood each beat but struggles to relax and fill properly, like a pump that can push water out but has trouble drawing enough back in between cycles. It matters to investors because it drives large and growing demand for treatments, hospital care and diagnostic tests, influences clinical trial design and regulatory decisions, and can affect the commercial prospects of drugs and medical devices.

PH-HFpEF medical

"gap among currently approved PH-HFpEF therapies."

Pulmonary hypertension associated with heart failure with preserved ejection fraction (PH‑HFpEF) is a condition where high blood pressure builds up in the lungs because the heart’s left side is stiff and doesn’t fill properly, even though its pumping strength looks normal. For investors, it matters because it defines a specific patient group and treatment need that shapes clinical trial design, drug approval chances, market size, and potential revenue for companies developing therapies; think of it as a distinct customer segment with a clear unmet need.

bispecific antibody medical

"iBio is engineering a selective bispecific antibody designed to block Activin A..."

A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.

Activin A medical

"designed to block Activin A, GDF8 (myostatin), and GDF11 to reduce cardiac fibrosis..."

Activin A is a naturally occurring protein that cells use to send signals controlling growth, inflammation and tissue repair; it often shows up in blood or tissue tests as a sign of disease activity. Investors watch it because changes in Activin A levels can point to the progress of conditions, serve as a target for new drugs, or affect regulatory decisions—like an alarm or thermometer that helps doctors and companies measure whether a treatment is working and how big a market the treatment might have.

AI-generated analysis. Not financial advice.

Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET

SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday, March 17, at 4 p.m. ET. The conference call will address iBio’s strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) and will include a presentation from Martin Brenner, DVM, Ph.D., iBio’s Chief Executive Officer and Chief Scientific Officer, and Cory Schwartz, Ph.D., the Company’s Director of Research and Early Development.

iBio is engineering a selective bispecific antibody designed to block Activin A, GDF8 (myostatin), and GDF11 to reduce cardiac fibrosis, reverse pulmonary vascular remodeling, and improve whole‑body functional capacity, while avoiding safety issues linked to broader TGF‑β ligand blockade. iBio’s bispecific approach is intentionally designed to target multiple core drivers of PH-HFpEF biology simultaneously, a gap among currently approved PH-HFpEF therapies. iBio expects to declare the optimized bispecific antibody development candidate for PH-HFpEF (validated for potency, selectivity, manufacturability, and in vivo efficacy) in the third quarter of calendar 2026 before entering IND‑enabling activities.

“Targeting PH-HFpEF represents an important step for our company and reflects conviction in our platform, program, and understanding of the biology,” said Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. “We believe our antibody approach has the potential to address key drivers of disease biology in an area where patients continue to face substantial unmet need. HFpEF affects millions worldwide, and our long-term vision is to build a family of therapies targeting core cardiometabolic pathways across the spectrum of cardiometabolic disease.”

Conference Call Details:

The webcast of the call may be accessed on the Investors section of the iBio website at ir.ibioinc.com/news-events/ir-calendar. A replay of the webcast will be available on the iBio website following the presentation.

To join the live call, participants need to access this link for dial-in numbers and a unique participation code.

About Heart Failure with Preserved Ejection Fraction (HFpEF)

Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome in which the heart continues to pump with a preserved ejection fraction but becomes impaired in its ability to relax and fill properly. HFpEF accounts for approximately half of all heart failure cases and is closely associated with obesity, diabetes, hypertension, and aging. Pulmonary hypertension associated with HFpEF (PH-HFpEF) is a clinically severe subtype linked to pulmonary vascular remodeling, reduced functional capacity, and poor prognosis. While current therapies have benefited many patients, there remains a significant unmet need for treatments that more directly modify the underlying drivers of disease.

About Myostatin x Activin A Bispecific

iBio’s bispecific antibody program targets three closely related ligands—myostatin (GDF8), GDF11, and Activin A, that sit at the intersection of skeletal muscle health, metabolic function, cardiac fibrosis, and vascular remodeling. Because these pathways can drive disease in both obesity/weight‑loss–related dysfunction and PH-HFpEF, iBio believes that the same selective mechanism of action may address both areas.

About iBio, Inc.

iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic and cardiopulmonary diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow iBio on LinkedIn.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding iBio engineering a selective bispecific antibody designed to block Activin A, GDF8 (myostatin), and GDF11 to reduce cardiac fibrosis, reverse pulmonary vascular remodeling, and improve whole‑body functional capacity, while avoiding safety issues linked to broader TGF‑β ligand blockade; iBio’s bispecific approach to intentionally design to target multiple core drivers of PH-HFpEF biology simultaneously, a gap among currently approved HFpEF therapies; iBio declaring the optimized bispecific antibody development candidate for HFpEF—validated for potency, selectivity, manufacturability, and in vivo efficacy—in the third quarter of calendar 2026 before entering IND‑enabling activities; iBio targeting PH-HFpEF reflects conviction in our platform, program, and understanding of the biology; iBio’s antibody approach having the potential to address key drivers of disease biology in an area where patients continue to face substantial unmet need; iBio’s long-term vision to build a family of therapies targeting core cardiometabolic pathways across the spectrum of cardiometabolic disease; IBIO-610’s potential as a differentiated therapy in obesity, cardiometabolic and cardiopulmonary diseases; filing an IND equivalent in the first half of calendar 2027; iBio’s ability to develop next-generation biopharmaceuticals for cardiometabolic, obesity and cardiopulmonary diseases, cancer and other hard-to-treat diseases; iBio’s ability to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs; and iBio’s ability to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to iBio on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, iBio’s ability to enter into IND‑enabling activities; iBio’s ability to develop a family of therapies targeting key cardiometabolic pathways that are able to address the full spectrum of cardiometabolic conditions, and that can support improving the lives of a rapidly growing patient population; the MoA being able to target the root cause of the disease rather than its symptoms; the same selective MoA addressing both obesity/weight‑loss–related dysfunction and HFpEF; filing an IND equivalent in the first half of calendar 2027; iBio’s ability to develop next-generation biopharmaceuticals for cardiometabolic, obesity and cardiopulmonary diseases, cancer and other hard-to-treat diseases; iBio’s ability to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs; and iBio’s ability to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine; iBio’s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio’s ability to promote or commercialize its product candidates for specific indications; acceptance of iBio’s product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio’s filings with the Securities and Exchange Commission (the “SEC”) including its Annual Report on Form 10-K for the year ended June 30, 2025 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Contact:

iBio, Inc. 
Investor Relations 
ir@ibioinc.com 

Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604

FAQ

What will iBio (IBIO) present on the March 17, 2026 conference call?

iBio will present its strategic pipeline expansion into PH-HFpEF and a bispecific antibody program. According to the company, the call includes talks by CEO Martin Brenner and Director Cory Schwartz and details on the selective bispecific antibody targeting Activin A, GDF8, and GDF11.

What is iBio's bispecific antibody targeting for PH-HFpEF (IBIO)?

The antibody is designed to block Activin A, GDF8 (myostatin), and GDF11 to address PH-HFpEF biology. According to the company, this selective approach aims to reduce cardiac fibrosis, reverse pulmonary vascular remodeling, and improve whole-body functional capacity.

When does iBio (IBIO) expect to nominate its PH-HFpEF development candidate?

iBio expects to declare an optimized bispecific development candidate in Q3 2026 before IND-enabling studies. According to the company, the candidate will be validated for potency, selectivity, manufacturability, and in vivo efficacy prior to that milestone.

How can investors access iBio's (IBIO) March 17, 2026 webcast and replay?

Investors can access the live webcast and replay via the Investors section of iBio's website. According to the company, the live call has dial-in numbers and a unique participation code available through the provided investor links.

What unmet needs does iBio (IBIO) say its PH-HFpEF program targets?

iBio says the bispecific approach targets multiple core drivers of PH-HFpEF biology where approved therapies have gaps. According to the company, the strategy aims to address disease drivers while avoiding safety issues tied to broader TGF-β ligand blockade.